Cargando…

Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer

BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assi...

Descripción completa

Detalles Bibliográficos
Autores principales: Piron, Sarah, De Man, Kathia, Schelfhout, Vanessa, Van Laeken, Nick, Kersemans, Ken, Achten, Eric, De Vos, Filip, Ost, Piet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040121/
https://www.ncbi.nlm.nih.gov/pubmed/32095919
http://dx.doi.org/10.1186/s13550-020-0593-7
_version_ 1783500923852554240
author Piron, Sarah
De Man, Kathia
Schelfhout, Vanessa
Van Laeken, Nick
Kersemans, Ken
Achten, Eric
De Vos, Filip
Ost, Piet
author_facet Piron, Sarah
De Man, Kathia
Schelfhout, Vanessa
Van Laeken, Nick
Kersemans, Ken
Achten, Eric
De Vos, Filip
Ost, Piet
author_sort Piron, Sarah
collection PubMed
description BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg (18)F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3 min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg. To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after administration of 2.0 ± 0.2 MBq/kg (18)F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and described all observed suspicious lesions. RESULTS: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180 min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group (p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion separately after more than 40 (18)F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65–0.92) to 0.94 (95% CI, 0.87–1). CONCLUSION: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to 2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of (18)F-PSMA-11 images. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018
format Online
Article
Text
id pubmed-7040121
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70401212020-03-10 Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer Piron, Sarah De Man, Kathia Schelfhout, Vanessa Van Laeken, Nick Kersemans, Ken Achten, Eric De Vos, Filip Ost, Piet EJNMMI Res Original Research BACKGROUND: Several scan parameters for PET imaging with (18)F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion visualization. Forty-four patients were randomly assigned to a dosage group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg (18)F-PSMA-11). All patients received a full-body PET/CT 1 h and 3 h after radiotracer injection with a scan duration of 3 min/bed position. For comparison of the scan duration, images were reconstructed for 1.5 and 3 min/bed position. Patients were intravenously administered 0.5 mg/kg furosemide with a maximum dose of 40 mg. To evaluate the furosemide effect, 22 additional patients were recruited and received one full-body PET/CT 1 h after administration of 2.0 ± 0.2 MBq/kg (18)F-PSMA-11 with a scan duration of 3 min/bed position. To this group, no furosemide was administered. Images were scored on image quality using a 7-point scale and each suspicious lesion was described. To assess interrater reliability, two nuclear physicians scored all scans independently and described all observed suspicious lesions. RESULTS: The 4 MBq/kg group received for all reconstructed images (60 min p.i., 1.5 and 3 min/bed position and 180 min p.i., 1.5 and 3 min/bed position) the highest median image quality score compared to the 2 MBq/kg group (p values < 0.01). When comparing all reconstructed images, the highest image quality score was given to images at 60 min p.i., 3 min/bed position for both dosage groups (score 5 and 6 for 2 and 4 MBq/kg, respectively). The addition of furosemide administration decreased the interference score with one point (p = 0.01106) and facilitated the evaluation of lesions in proximity to the ureters. The interrater reliability for the comparison of each lesion separately after more than 40 (18)F-PSMA-11 scan readings showed an increasing κ value from 0.78 (95% CI, 0.65–0.92) to 0.94 (95% CI, 0.87–1). CONCLUSION: Although the results indicate an administered activity of 4.0 ± 0.4 MBq/kg, preference will be given to 2.0 ± 0.2 MBq/kg due to the small difference in absolute score (max 1 point) and the ALARA principle. For evaluation of lesions in proximity to the ureters, the co-administration of a diuretic can be useful. The increase of the κ value from 0.78 to 0.94 suggests a learning curve in the interpretation of (18)F-PSMA-11 images. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03573011. Retrospectively registered 28 June 2018 Springer Berlin Heidelberg 2020-02-24 /pmc/articles/PMC7040121/ /pubmed/32095919 http://dx.doi.org/10.1186/s13550-020-0593-7 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Piron, Sarah
De Man, Kathia
Schelfhout, Vanessa
Van Laeken, Nick
Kersemans, Ken
Achten, Eric
De Vos, Filip
Ost, Piet
Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title_full Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title_fullStr Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title_full_unstemmed Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title_short Optimization of PET protocol and interrater reliability of (18)F-PSMA-11 imaging of prostate cancer
title_sort optimization of pet protocol and interrater reliability of (18)f-psma-11 imaging of prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040121/
https://www.ncbi.nlm.nih.gov/pubmed/32095919
http://dx.doi.org/10.1186/s13550-020-0593-7
work_keys_str_mv AT pironsarah optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT demankathia optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT schelfhoutvanessa optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT vanlaekennick optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT kersemansken optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT achteneric optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT devosfilip optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer
AT ostpiet optimizationofpetprotocolandinterraterreliabilityof18fpsma11imagingofprostatecancer